Your browser doesn't support javascript.
The immunodominant and neutralization linear epitopes for SARS-CoV-2.
Lu, Shuai; Xie, Xi-Xiu; Zhao, Lei; Wang, Bin; Zhu, Jie; Yang, Ting-Rui; Yang, Guang-Wen; Ji, Mei; Lv, Cui-Ping; Xue, Jian; Dai, Er-Hei; Fu, Xi-Ming; Liu, Dong-Qun; Zhang, Lun; Hou, Sheng-Jie; Yu, Xiao-Lin; Wang, Yu-Ling; Gao, Hui-Xia; Shi, Xue-Han; Ke, Chang-Wen; Ke, Bi-Xia; Jiang, Chun-Guo; Liu, Rui-Tian.
  • Lu S; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Xie XX; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Zhao L; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Wang B; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Zhu J; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Yang TR; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Yang GW; Department of Computer Science and Technology, Tsinghua University, Beijing 100084, China.
  • Ji M; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
  • Lv CP; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
  • Xue J; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Dai EH; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Fu XM; The Chinese University of Hong Kong, Shenzhen 518172, China; University of Science and Technology, Hefei 230026, China.
  • Liu DQ; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
  • Zhang L; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
  • Hou SJ; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China.
  • Yu XL; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.
  • Wang YL; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Gao HX; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Shi XH; Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.
  • Ke CW; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Ke BX; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China.
  • Jiang CG; Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: jiang_cg@163.com.
  • Liu RT; National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China. Electronic address: rtliu@ipe.ac.cn.
Cell Rep ; 34(4): 108666, 2021 01 26.
Article in English | MEDLINE | ID: covidwho-1064915
ABSTRACT
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are under development, the antigen epitopes on the virus and their immunogenicity are poorly understood. Here, we simulate the 3D structures and predict the B cell epitopes on the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 using structure-based approaches and validate epitope immunogenicity by immunizing mice. Almost all 33 predicted epitopes effectively induce antibody production, six of these are immunodominant epitopes in individuals, and 23 are conserved within SARS-CoV-2, SARS-CoV, and bat coronavirus RaTG13. We find that the immunodominant epitopes of individuals with domestic (China) SARS-CoV-2 are different from those of individuals with imported (Europe) SARS-CoV-2, which may be caused by mutations on the S (G614D) and N proteins. Importantly, we find several epitopes on the S protein that elicit neutralizing antibodies against D614 and G614 SARS-CoV-2, which can contribute to vaccine design against coronaviruses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Matrix Proteins / Epitopes, B-Lymphocyte / Spike Glycoprotein, Coronavirus / Viroporin Proteins / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Animals / Child / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2020.108666

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Matrix Proteins / Epitopes, B-Lymphocyte / Spike Glycoprotein, Coronavirus / Viroporin Proteins / Coronavirus Nucleocapsid Proteins / SARS-CoV-2 Type of study: Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Aged / Animals / Child / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Year: 2021 Document Type: Article Affiliation country: J.celrep.2020.108666